Catalyst Wire Dossier Catalyst Wire Dossier

Uprifosbuvir

uprifosbuvir · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

7 regulatory and trial events tracked for Uprifosbuvir, covering 2017-12-21 to 2018-12-26. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041) [Phase 2]

See pricing